论文部分内容阅读
目的:依达拉奉联合应用奥扎格雷钠药物治疗急性脑梗死所取得的临床效果进行分析研究。方法:从在我院接受诊治的急性脑梗死患者中选取104例作为研究对象,依据治疗方法不同将患者平均分为两组,对照组使用依达拉奉药物治疗;而观察组在使依达拉奉的同时联合奥扎格雷钠药物治疗,观察并比较两组患者不同治疗方法所取得的临床效果。结果:治疗后,对照组总有效率(65.38%)明显低于观察组总有效率(90.38%);对照组在治疗期间消化道反应、出血倾向、注射部位疼痛以及过敏反应并发症的发生率(40.38%)明显高于观察组(13.46%),具有统计学意义(p<0.05)。结论:用依达拉奉联合奥扎格雷钠治疗该疾病不仅药物起效较快,而且有效缓解患者临床症状,可在临床广泛应用。
Objective: Edaravone combined application of ozagrel sodium in the treatment of acute cerebral infarction clinical results were analyzed. Methods: A total of 104 patients with acute cerebral infarction who were diagnosed and treated in our hospital were enrolled in this study. Patients were divided equally into two groups according to different treatment methods. The control group was treated with edaravone. In the observation group, At the same time, we also combined the drug of ozagrel sodium to observe and compare the clinical effects of different treatment methods in both groups. Results: After treatment, the total effective rate (65.38%) in the control group was significantly lower than that in the observation group (90.38%). The incidence of gastrointestinal reactions, bleeding tendency, pain in the injection site and the incidence of anaphylactic reaction in the control group (40.38%) was significantly higher than the observation group (13.46%), with statistical significance (p <0.05). Conclusion: The combination of edaravone and ozagrel sodium can not only quicken the onset of drugs, but also effectively alleviate the clinical symptoms of patients. It can be widely used clinically.